Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06114706
Other study ID # U1111-1299-3543
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 4, 2024
Est. completion date December 31, 2026

Study information

Verified date April 2024
Source Vastra Gotaland Region
Contact Carl Wikberg, PhD
Phone +46703821660
Email carl.wikberg@allmed.gu.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to investigate if an organisational change of patient flow away from medical practitioners can reduce unnecessary antibiotic prescribing in patients attending with a sore throat as the main complaint.


Description:

Today patients appear either at a PHC centre or at the Pharmacy. The Pharmacy may provide advice on analgesic or refer the patient to a PHC centre. At the PHC centre, the patient may first appear to the medical practitioner or a nurse pending on local routines. The current Swedish guideline recommends no antibiotics and no testing for patients with 0-2 Centor criteria. For patients with 3-4 Centor criteria the guideline recommends testing and only consider antibiotics if GAS is present. COVID-19 has gradually transformed from expressing itself as a severe lower respiratory tract infection to be more of an upper respiratory tract infection. Furthermore, COVID-19 is likely to transform from a pandemic to an endemic state with a low continuous incidence. Hence, in response to COVID-19 it seems crucial to identify to what extent the common sore throat is caused by the SARS-CoV-2. Furthermore, a large controlled clinical trial is required to sort out if patients attending with a sore throat as the main complaint are best managed by medical practitioners, nurses or pharmacists. This study aims to perform such a controlled clinical trial comparing the outcome of sore throat patients management by medical practitioner, nurses and pharmacists. This study also aims to investigate to what extent the SARS-CoV-2 virus is identified in these patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 450
Est. completion date December 31, 2026
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria: - The patient is contacting/attending PHC centre or Pharmacy presenting with a sore throat as the main complaint. - Male or female, aged =6 years. - Fluent in Swedish (reading, writing, conversational) (applicable to caregivers/parents/guardians in case of children). - Mental state such that he or she can understand and give informed consent to participation in the study by signing the Information and Consent Form. - Provision of signed and dated Informed Consent Form. Exclusion Criteria: - The illness episode is classified as potentially complicated or potentially critically ill - Presence of SARS-CoV-2 virus in a patient first appearing at the PHC in a cluster where the assessment is supposed to be done by the pharmacists. The patient will not be sent to the pharmacist in case of presence of SARS-CoV-2-virus. - Patient request to be withdrawn from the study.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Physicians assess patients
Physicians are asked to assess patients following the current Swedish guideline
Nurses assess patients
Nurses are asked to assess patients following the current Swedish guideline
Pharmacists assess patients
Pharmacists are asked to assess patients following the current Swedish guideline

Locations

Country Name City State
Sweden Apoteket Stenungsund
Sweden Närhälsan Stenungsund Vårdcentral Stenungsund
Sweden Apoteksgruppen Ulricehamn
Sweden Praktikertjänst Hälsobrunnen Vårdcentral Ulricehamn

Sponsors (2)

Lead Sponsor Collaborator
Vastra Gotaland Region Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Guideline adherence Will the proportion of patients attending for an uncomplicated acute sore throat being managed according to prevailing guidelines differ if the initial assessment is made by a medical practitioner, a trained nurse or a trained pharmacist Immediately after the consultation
Secondary Illness severity What proportion of patients attending PHC centres or pharmacies are classified as apparently uncomplicated, potentially complicated or potentially critically ill Immediately after the consultation
Secondary Type of patients seeking care Will patient characteristics differ if the patient first appears to the medical practitioner, a trained nurse or a trained pharmacist? Immediately after the consultation
Secondary Presence of SARS-CoV-2 virus To what extent do patients attending Primary Health Care/Pharmacies due to an acute sore throat harbour the SARS-CoV-2 virus? Immediately after the consultation
See also
  Status Clinical Trial Phase
Completed NCT01453400 - Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain Phase 3
Completed NCT04016051 - Acceptance of Clarithromycin in a Straw Compared to Syrup in Children With Upper Respiratory Tract Infections Phase 3
Recruiting NCT01681667 - Tablet vs. Liquid Suspension Ibuprofen in the Relief of Pain Phase 4
Completed NCT00527852 - Assessment of Flocked Swabs for the Identification of Group A Streptococcal Pharyngitis N/A
Completed NCT02178293 - Ketoprofen Lysine Salt as Mouthwash in Acute Phlogosis of the Pharyngeal Cavity Versus Benzidamine Hydrochloride Phase 4
Active, not recruiting NCT05127161 - Broad Implementation of Outpatient Stewardship N/A
Withdrawn NCT02535962 - Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA) Phase 2
Not yet recruiting NCT02252419 - Combined Effect of Dexamethasone and Paracetamol for Postoperative Sore Throat N/A
Completed NCT00798018 - Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence Phenomena N/A
Completed NCT00535093 - An Assessment of Rapid Streptococcal Tests in Community Clinics in Israel N/A
Completed NCT00148499 - Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis Phase 3
Completed NCT00095368 - APC-111 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) for 10 Days in Patients With Strep Throat Phase 3
Recruiting NCT06027593 - Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions N/A
Recruiting NCT03720301 - The Use of Osteopathic Medical Manipulation to Decrease the Incidence and Severity of Post-Operative Sore Throat N/A
Completed NCT01361399 - Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold Phase 3
Completed NCT01049334 - A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis Phase 3
Completed NCT01398696 - Impact of Four Patient Information Leaflets (PIL) on Patient Behaviour Phase 4
Completed NCT01048866 - A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis Phase 3
Completed NCT00547391 - Recurrent Throat Infections and Tonsillectomy Phase 4
Completed NCT00242281 - APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat Phase 3